Loading
KIF18A is a motor protein that keeps chromosomes lined up during cell division. Tumour cells with unstable chromosome numbers depend on it while normal cells largely do not, which is the case for the KIF18A inhibitors now in early trials. This dossier gathers the 1 product (0 approved), 1 trial, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Plus-end-directed kinesin-8 motor that shortens kinetochore microtubules, reducing chromosome oscillations before anaphase (UniProt Q8NI77).
| Modality | Phase 1 |
|---|---|
| Small molecule 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 1/2 | Recruiting | A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Locally Advanced or Metastatic Solid Tumors, Including High-Grade Serous Ovarian Cancer | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"KIF18A" OR ABSTRACT:"KIF18A" OR TITLE:"kinesin family member 18A" OR ABSTRACT:"kinesin family member 18A" OR TITLE:"kinesin-8" OR ABSTRACT:"kinesin-8") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KIF18A, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/kif18a.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/kif18a.json. Licence CC BY-NC 4.0.